Cargando…
Immunohistochemical and molecular analyses of HER2 status in breast cancers are highly concordant and complementary approaches
BACKGROUND: Immunohistochemistry (IHC) and fluorescent in situ hybridisation (FISH) are currently the most commonly used methods to assess HER2 status. PCR-based assays allow quantitative determination of HER2 amplification (Q-PCR) or overexpression (Q-RT–PCR), but are not routinely used. We evaluat...
Autores principales: | , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3111154/ https://www.ncbi.nlm.nih.gov/pubmed/21540864 http://dx.doi.org/10.1038/bjc.2011.135 |
_version_ | 1782205588444282880 |
---|---|
author | Lehmann-Che, J Amira-Bouhidel, F Turpin, E Antoine, M Soliman, H Legres, L Bocquet, C Bernoud, R Flandre, E Varna, M de Roquancourt, A Plassa, L-F Giacchetti, S Espié, M de Bazelaire, C Cahen-Doidy, L Bourstyn, E Janin, A de Thé, H Bertheau, P |
author_facet | Lehmann-Che, J Amira-Bouhidel, F Turpin, E Antoine, M Soliman, H Legres, L Bocquet, C Bernoud, R Flandre, E Varna, M de Roquancourt, A Plassa, L-F Giacchetti, S Espié, M de Bazelaire, C Cahen-Doidy, L Bourstyn, E Janin, A de Thé, H Bertheau, P |
author_sort | Lehmann-Che, J |
collection | PubMed |
description | BACKGROUND: Immunohistochemistry (IHC) and fluorescent in situ hybridisation (FISH) are currently the most commonly used methods to assess HER2 status. PCR-based assays allow quantitative determination of HER2 amplification (Q-PCR) or overexpression (Q-RT–PCR), but are not routinely used. We evaluated the relevance of Q-RT–PCR for HER2 status determination. METHODS: We compared IHC and Q-RT–PCR in 466 breast tumours. In discordant or equivocal cases, five additional methods (IHC with two other antibodies, FISH, silver in situ hybridisation (SISH) and Q-PCR) were combined to determine HER2 status. Two cases with HER2 intra-tumour heterogeneity were further explored by allelic profiles analysis and HUMARA clonality determination after microdissection. RESULTS: We observed 97.3% concordance between Q-RT–PCR and non-equivocal IHC. Twelve out of 466 cases (3%) revealed discordances between the two methods. The power of Q-RT–PCR to predict HER2 status (defined by seven methods) was similar to that of IHC. Although rare, some discordances between techniques might be due to HER2 intra-tumour heterogeneity and we report two examples, one tumour containing two distinct clones, another tumour consisting of HER2 amplified and non-amplified subclones. CONCLUSION: Q-RT–PCR and IHC are highly concordant methods for HER2 status assessment, and Q-RT–PCR allows a highly reliable quantitative assessment and could be a useful adjunct to IHC. |
format | Online Article Text |
id | pubmed-3111154 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-31111542012-05-24 Immunohistochemical and molecular analyses of HER2 status in breast cancers are highly concordant and complementary approaches Lehmann-Che, J Amira-Bouhidel, F Turpin, E Antoine, M Soliman, H Legres, L Bocquet, C Bernoud, R Flandre, E Varna, M de Roquancourt, A Plassa, L-F Giacchetti, S Espié, M de Bazelaire, C Cahen-Doidy, L Bourstyn, E Janin, A de Thé, H Bertheau, P Br J Cancer Molecular Diagnostics BACKGROUND: Immunohistochemistry (IHC) and fluorescent in situ hybridisation (FISH) are currently the most commonly used methods to assess HER2 status. PCR-based assays allow quantitative determination of HER2 amplification (Q-PCR) or overexpression (Q-RT–PCR), but are not routinely used. We evaluated the relevance of Q-RT–PCR for HER2 status determination. METHODS: We compared IHC and Q-RT–PCR in 466 breast tumours. In discordant or equivocal cases, five additional methods (IHC with two other antibodies, FISH, silver in situ hybridisation (SISH) and Q-PCR) were combined to determine HER2 status. Two cases with HER2 intra-tumour heterogeneity were further explored by allelic profiles analysis and HUMARA clonality determination after microdissection. RESULTS: We observed 97.3% concordance between Q-RT–PCR and non-equivocal IHC. Twelve out of 466 cases (3%) revealed discordances between the two methods. The power of Q-RT–PCR to predict HER2 status (defined by seven methods) was similar to that of IHC. Although rare, some discordances between techniques might be due to HER2 intra-tumour heterogeneity and we report two examples, one tumour containing two distinct clones, another tumour consisting of HER2 amplified and non-amplified subclones. CONCLUSION: Q-RT–PCR and IHC are highly concordant methods for HER2 status assessment, and Q-RT–PCR allows a highly reliable quantitative assessment and could be a useful adjunct to IHC. Nature Publishing Group 2011-05-24 2011-05-03 /pmc/articles/PMC3111154/ /pubmed/21540864 http://dx.doi.org/10.1038/bjc.2011.135 Text en Copyright © 2011 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Molecular Diagnostics Lehmann-Che, J Amira-Bouhidel, F Turpin, E Antoine, M Soliman, H Legres, L Bocquet, C Bernoud, R Flandre, E Varna, M de Roquancourt, A Plassa, L-F Giacchetti, S Espié, M de Bazelaire, C Cahen-Doidy, L Bourstyn, E Janin, A de Thé, H Bertheau, P Immunohistochemical and molecular analyses of HER2 status in breast cancers are highly concordant and complementary approaches |
title | Immunohistochemical and molecular analyses of HER2 status in breast cancers are highly concordant and complementary approaches |
title_full | Immunohistochemical and molecular analyses of HER2 status in breast cancers are highly concordant and complementary approaches |
title_fullStr | Immunohistochemical and molecular analyses of HER2 status in breast cancers are highly concordant and complementary approaches |
title_full_unstemmed | Immunohistochemical and molecular analyses of HER2 status in breast cancers are highly concordant and complementary approaches |
title_short | Immunohistochemical and molecular analyses of HER2 status in breast cancers are highly concordant and complementary approaches |
title_sort | immunohistochemical and molecular analyses of her2 status in breast cancers are highly concordant and complementary approaches |
topic | Molecular Diagnostics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3111154/ https://www.ncbi.nlm.nih.gov/pubmed/21540864 http://dx.doi.org/10.1038/bjc.2011.135 |
work_keys_str_mv | AT lehmannchej immunohistochemicalandmolecularanalysesofher2statusinbreastcancersarehighlyconcordantandcomplementaryapproaches AT amirabouhidelf immunohistochemicalandmolecularanalysesofher2statusinbreastcancersarehighlyconcordantandcomplementaryapproaches AT turpine immunohistochemicalandmolecularanalysesofher2statusinbreastcancersarehighlyconcordantandcomplementaryapproaches AT antoinem immunohistochemicalandmolecularanalysesofher2statusinbreastcancersarehighlyconcordantandcomplementaryapproaches AT solimanh immunohistochemicalandmolecularanalysesofher2statusinbreastcancersarehighlyconcordantandcomplementaryapproaches AT legresl immunohistochemicalandmolecularanalysesofher2statusinbreastcancersarehighlyconcordantandcomplementaryapproaches AT bocquetc immunohistochemicalandmolecularanalysesofher2statusinbreastcancersarehighlyconcordantandcomplementaryapproaches AT bernoudr immunohistochemicalandmolecularanalysesofher2statusinbreastcancersarehighlyconcordantandcomplementaryapproaches AT flandree immunohistochemicalandmolecularanalysesofher2statusinbreastcancersarehighlyconcordantandcomplementaryapproaches AT varnam immunohistochemicalandmolecularanalysesofher2statusinbreastcancersarehighlyconcordantandcomplementaryapproaches AT deroquancourta immunohistochemicalandmolecularanalysesofher2statusinbreastcancersarehighlyconcordantandcomplementaryapproaches AT plassalf immunohistochemicalandmolecularanalysesofher2statusinbreastcancersarehighlyconcordantandcomplementaryapproaches AT giacchettis immunohistochemicalandmolecularanalysesofher2statusinbreastcancersarehighlyconcordantandcomplementaryapproaches AT espiem immunohistochemicalandmolecularanalysesofher2statusinbreastcancersarehighlyconcordantandcomplementaryapproaches AT debazelairec immunohistochemicalandmolecularanalysesofher2statusinbreastcancersarehighlyconcordantandcomplementaryapproaches AT cahendoidyl immunohistochemicalandmolecularanalysesofher2statusinbreastcancersarehighlyconcordantandcomplementaryapproaches AT bourstyne immunohistochemicalandmolecularanalysesofher2statusinbreastcancersarehighlyconcordantandcomplementaryapproaches AT janina immunohistochemicalandmolecularanalysesofher2statusinbreastcancersarehighlyconcordantandcomplementaryapproaches AT detheh immunohistochemicalandmolecularanalysesofher2statusinbreastcancersarehighlyconcordantandcomplementaryapproaches AT bertheaup immunohistochemicalandmolecularanalysesofher2statusinbreastcancersarehighlyconcordantandcomplementaryapproaches |